Graham J, Luthra R, Earnshaw S, Borker R. Cost-effectiveness of afatinib vs. erlotinib in the 1st-line treatment of metastatic NSCLC patients with EGFR exon 19 deletion mutations. Poster presented at the 16th World Conference on Lung Cancer; September 6, 2015. Denver, CO.